According to a recent press release, Quadrant Biosciences Inc. has entered into licensing agreements with State of New York (SUNY) Upstate Medical University and Penn State University for the commercialization of novel epigenetic biomarkers for concussion as well as autism spectrum disorder (ASD) and Parkinson’s disease.
Quadrant Biosciences to Commercialize Concussion Biomarker
1 min read Premium comments
Secondary#concussion#quandrantbiosciences
Quadrant Biosciences, a Life Science company headquartered in Syracuse, New York, has been working with these two institutions for several years on developing tests to support early diagnosis for these health issues. The first biologic diagnostic aid to come out later this year will be the one for ASD.
This novel biomarker technology is able to provide an early diagnosis based on the concentration of ribonucleic acid (RNA) molecules measured in the saliva. According to the release, multiple studies conducted by SUNY Upstate and Penn State which were supported by Quadrant Biosciences have confirmed a high concentration of these RNA molecules in the saliva of patients with ASD, Parkinson’s disease and concussion.
“There have been many attempts to develop biologic tests to help diagnose neurological or neurodevelopmental disorders, primarily using genetic and blood-based assays. Our epigenetic approach looking at RNAs in saliva is highly novel and provides a more robust method of distinguishing affected from unaffected subjects,” Frank Middleton, Ph.D. at SUNY Upstate Medical University said in the release.
Steve Hicks, M.D., PhD., a pediatrician at Penn State College of Medicine added, “This epigenetic platform provides an opportunity for clinicians to quickly and objectively assess medical conditions that have historically relied on expert medical opinions. This represents an important step in the development of clinical tools that will revolutionize the way we diagnose and treat our patients.”
For more information, visit www.QuadrantBiosciences.com.
React:
Discussion
This is a fascinating development. In my practice we've seen similar outcomes with the revised protocol. The key differentiator seems to be patient selection criteria. Has anyone else noticed the correlation with BMI thresholds?
Great point. I'd push back slightly on the conclusion, the sample size in the cited study is too small to draw population-level inferences. That said, the directional signal is compelling and worth a larger RCT.
We implemented a similar approach last year. Early results are promising but we're still gathering 12-month follow-up data. Happy to share our protocol if anyone is interested.
Join the conversation
Orthopedic professionals are discussing this. Sign in and upgrade to read every comment and add your voice.